BRPI1013179A2 - peptídeo sintético, métodos para detectar um anticorpo de proteína anti-citrulinado em uma amostra biológica, para realizar um ensaio para ajudar no diagnóstico ou prognóstico de artrite reumatóide, para melhorar a sensibilidade de diagnosticar ou prognosticar artrite reumatóide, ensaio para diagnosticar ou prognosticar artrite reumatóide, kit, e, método para identificar um peptídeo que é imunologicamente reativo com um anticorpo de proteína anti-citrulinado - Google Patents

peptídeo sintético, métodos para detectar um anticorpo de proteína anti-citrulinado em uma amostra biológica, para realizar um ensaio para ajudar no diagnóstico ou prognóstico de artrite reumatóide, para melhorar a sensibilidade de diagnosticar ou prognosticar artrite reumatóide, ensaio para diagnosticar ou prognosticar artrite reumatóide, kit, e, método para identificar um peptídeo que é imunologicamente reativo com um anticorpo de proteína anti-citrulinado

Info

Publication number
BRPI1013179A2
BRPI1013179A2 BRPI1013179A BRPI1013179A BRPI1013179A2 BR PI1013179 A2 BRPI1013179 A2 BR PI1013179A2 BR PI1013179 A BRPI1013179 A BR PI1013179A BR PI1013179 A BRPI1013179 A BR PI1013179A BR PI1013179 A2 BRPI1013179 A2 BR PI1013179A2
Authority
BR
Brazil
Prior art keywords
rheumatoid arthritis
assay
protein antibody
citrullinated protein
peptide
Prior art date
Application number
BRPI1013179A
Other languages
English (en)
Inventor
Wang Dunrui
Chi-Kwan Ling Nicholas
Singh Sharat
Long Wang Shui
Original Assignee
Prometheus Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometheus Laboratories Inc filed Critical Prometheus Laboratories Inc
Priority to BR122013006960-7A priority Critical patent/BR122013006960A2/pt
Publication of BRPI1013179A2 publication Critical patent/BRPI1013179A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
BRPI1013179A 2009-03-30 2010-03-26 peptídeo sintético, métodos para detectar um anticorpo de proteína anti-citrulinado em uma amostra biológica, para realizar um ensaio para ajudar no diagnóstico ou prognóstico de artrite reumatóide, para melhorar a sensibilidade de diagnosticar ou prognosticar artrite reumatóide, ensaio para diagnosticar ou prognosticar artrite reumatóide, kit, e, método para identificar um peptídeo que é imunologicamente reativo com um anticorpo de proteína anti-citrulinado BRPI1013179A2 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122013006960-7A BR122013006960A2 (pt) 2009-03-30 2010-03-26 Peptídeo sintético que é imunologicamente reativo com um anticorpo de proteína anti-citrulinado, seu uso e seu método de identificação, bem como kit compreendendo o referido peptídeo

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16484009P 2009-03-30 2009-03-30
US24349609P 2009-09-17 2009-09-17
US25505809P 2009-10-26 2009-10-26
PCT/US2010/028946 WO2010117694A2 (en) 2009-03-30 2010-03-26 Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis

Publications (1)

Publication Number Publication Date
BRPI1013179A2 true BRPI1013179A2 (pt) 2019-09-24

Family

ID=42651163

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122013006960-7A BR122013006960A2 (pt) 2009-03-30 2010-03-26 Peptídeo sintético que é imunologicamente reativo com um anticorpo de proteína anti-citrulinado, seu uso e seu método de identificação, bem como kit compreendendo o referido peptídeo
BRPI1013179A BRPI1013179A2 (pt) 2009-03-30 2010-03-26 peptídeo sintético, métodos para detectar um anticorpo de proteína anti-citrulinado em uma amostra biológica, para realizar um ensaio para ajudar no diagnóstico ou prognóstico de artrite reumatóide, para melhorar a sensibilidade de diagnosticar ou prognosticar artrite reumatóide, ensaio para diagnosticar ou prognosticar artrite reumatóide, kit, e, método para identificar um peptídeo que é imunologicamente reativo com um anticorpo de proteína anti-citrulinado

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122013006960-7A BR122013006960A2 (pt) 2009-03-30 2010-03-26 Peptídeo sintético que é imunologicamente reativo com um anticorpo de proteína anti-citrulinado, seu uso e seu método de identificação, bem como kit compreendendo o referido peptídeo

Country Status (8)

Country Link
US (2) US8519096B2 (pt)
EP (2) EP3070097A3 (pt)
AU (1) AU2010234942B2 (pt)
BR (2) BR122013006960A2 (pt)
CA (1) CA2757444A1 (pt)
IL (2) IL225538A0 (pt)
NZ (2) NZ608489A (pt)
WO (1) WO2010117694A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404932B2 (en) * 2007-11-05 2016-08-02 Nordic Bioscience A/S Pathology biomarker assay
HUE044239T2 (hu) 2008-03-27 2019-10-28 Purdue Research Foundation Kollagén-kötõ szintetikus peptidoglikánok, elõállításuk és alkalmazási eljárásaik
EP2402368A1 (en) 2010-07-02 2012-01-04 Toscana Biomarkers S.r.l. Histone citrullinated peptides and uses thereof
CA2817847C (en) * 2010-11-12 2018-02-13 The Johns Hopkins University Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
US10309974B2 (en) 2010-11-12 2019-06-04 Cedars-Sinai Medical Center Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
GB201101740D0 (en) 2011-02-01 2011-03-16 Haemostatix Ltd Therapeutic agents with improved fibrinogen binding
US20150218546A1 (en) * 2011-04-05 2015-08-06 Lars Klareskog Novel peptides that bind to types of mhc class ii and their use on diagnosis and treatment
ES2560012T3 (es) * 2011-05-10 2016-02-17 Institut National De La Santé Et De La Recherche Médicale (Inserm) Métodos y composiciones farmacéuticas para el tratamiento de enfermedades autoinmunitarias
EP2527841A1 (en) 2011-05-25 2012-11-28 Toscana Biomarkers S.r.l. Methods for the diagnosis of rheumatoid arthritis
WO2012163768A1 (en) * 2011-05-27 2012-12-06 Nordic Bioscience A/S Detection of diagnostic peptides
WO2013105721A1 (ko) * 2012-01-13 2013-07-18 가톨릭대학교 산학협력단 류마티스 관절염 진단 키트
US9347941B2 (en) 2012-01-13 2016-05-24 Catholic University Industry-Academic Cooperation Foundation Diagnosis kit for rheumatoid arthritis
US20130274125A1 (en) * 2012-04-16 2013-10-17 Bio-Rad Laboratories Inc. Multiplex immunoassay for rheumatoid arthritis and other autoimmune diseases
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
WO2014141244A1 (en) * 2013-03-12 2014-09-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Synthetic peptides for the treatment of autoimmune diseases
EP2970509B1 (en) 2013-03-15 2020-05-13 Purdue Research Foundation Extracellular matrix-binding synthetic peptidoglycans
CA2923553C (en) 2013-09-13 2023-05-23 Soligenix, Inc. Novel peptides and analogs for use in the treatment of oral mucositis
US11311598B2 (en) 2013-09-13 2022-04-26 Soligenix, Inc. Peptides and analogs for use in the treatment of oral mucositis
WO2015164822A1 (en) 2014-04-25 2015-10-29 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
EP3311176A4 (en) 2015-06-18 2019-03-13 Cedars-Sinai Medical Center ROLE OF CITRULLINATION IN THE DIAGNOSIS OF ILLNESSES
GB201512703D0 (en) 2015-07-20 2015-08-26 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
WO2019010484A2 (en) 2017-07-07 2019-01-10 Symic Ip, Llc SYNTHETIC BIOCONJUGATES
CN110862450A (zh) * 2018-08-28 2020-03-06 东莞光极生物科技有限公司 基于cii的环状多肽及其应用
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
CN110041404B (zh) * 2019-04-08 2020-10-09 北京大学人民医院(北京大学第二临床医学院) 瓜氨酸化抗原修饰肽及其应用
CN114573663B (zh) * 2019-08-27 2023-08-11 广东菲鹏生物有限公司 瓜氨酸肽及其应用、类风湿关节炎的检测试剂与试剂盒
WO2021038283A1 (en) * 2019-08-30 2021-03-04 Universidad De Chile Autoantigenic peptides (calvicifiv), presented by tolerogenic dentritic cells, useful for the personalized treatment of rheumatoid arthritis
CN113004421B (zh) * 2021-02-18 2022-05-17 青岛硕景生物科技有限公司 一种检测抗瓜氨酸肽抗体的ccp抗原及其制备方法
CA3220978A1 (en) * 2021-06-01 2022-12-08 Lars Klareskog Novel peptide mimics and their use
CN115060897A (zh) * 2021-07-01 2022-09-16 浙江大学 一种检测抗Prelamin A/C-IgG抗体的试剂盒
WO2024117967A1 (en) * 2022-12-01 2024-06-06 Dubnovitsky Anatoly Peptide mimics and their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
AU2155899A (en) * 1997-11-28 1999-06-16 Innogenetics N.V. Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
AU2004216925B2 (en) * 2003-03-07 2010-04-22 London Health Sciences Centre Research Inc. Peptides associated with HLA-DR MHC class II molecules involved in autoimmune diseases
DE102005029845B4 (de) 2005-06-27 2017-03-23 Orgentec Diagnostika Gmbh Verfahren zur Diagnose von rheumatischen Erkrankungen
AU2008277776A1 (en) * 2007-07-13 2009-01-22 Celecure As Novel inhibitor of angiogenesis

Also Published As

Publication number Publication date
US20120295280A1 (en) 2012-11-22
WO2010117694A2 (en) 2010-10-14
EP3070097A3 (en) 2016-11-23
IL225538A0 (en) 2013-06-27
CA2757444A1 (en) 2010-10-14
BR122013006960A2 (pt) 2019-10-15
US20140170683A1 (en) 2014-06-19
US8519096B2 (en) 2013-08-27
WO2010117694A3 (en) 2011-01-20
EP3070097A2 (en) 2016-09-21
EP2414390A2 (en) 2012-02-08
NZ595310A (en) 2013-05-31
NZ608489A (en) 2014-08-29
AU2010234942A1 (en) 2011-10-27
AU2010234942B2 (en) 2015-03-05
IL215337A (en) 2017-02-28
IL215337A0 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
NZ600828A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112012009846A2 (pt) ensaios para detecção de anticorpos específicos para anticorpos anti-ige terapêuticos e seu uso em anafilaxia
WO2010117694A3 (en) Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis
BR112013003391B8 (pt) Método para diagnosticar câncer pancreático em um indivíduo
NZ619883A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3156925A3 (en) Copd biomarker signatures
BRPI0618713B8 (pt) cardiolipina modificada e seus usos
IN2014CN01787A (pt)
EA201290311A1 (ru) Факторы риска и прогнозирование инфаркта миокарда
BRPI0923199B8 (pt) método para determinar a presença de anticorpos de fixação de complemento
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
GB201120209D0 (en) Methods of monitoring conditions by sequence analysis
BR112012017014A8 (pt) métodos para detecção de anticorpos de vírus jc
WO2010002911A3 (en) Methods and materials for monitoring myeloma using quantitative mass spetrometry
JP2012522232A5 (pt)
MX2009013009A (es) Inmunoensayos de alta sensibilidad y kits para la determinacion de peptidos y proteinas de interes biologico.
EP3182126A3 (en) Biomarker test for prediction or early detection of preeclampsia and/or hellp syndrome
EP2010912A4 (en) PREDICTION OF LETALITY AND DETECTION OF SERIOUS DISEASES
DK2791675T3 (da) Måling af autoantistoffer under lav ledeevne-betingelser
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP1891108A4 (en) PSP94 DIAGNOSTICS AND ASSAYS
WO2012021741A3 (en) Lateral flow assays for non-diagnostic analytes
WO2008136510A1 (ja) 自己免疫性膵炎及び劇症１型糖尿病の検査方法及び検査試薬
EP2565647A4 (en) REAGENT TO TEST AN ANTIBODY AGAINST TREPONEMA PALLIDUM
WO2010006199A3 (en) Immunoassays for the detection of anti -non-muscle myosin heavy chain (nmhc)-ii autoantibodies in cardiovascular diseases

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: NESTEC S.A. (CH)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.